Article

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer

2022-10-13

Abstract excerpt

<h4>Background: </h4> MammaPrint (MMP) helps clinicians identify the ideal time for adjuvant treatment for patients with early HR+/HER2- breast cancer. We aimed to externally validate a nomogram designed to predict probability of low risk of MMP results and to evaluate the difference in survival outcome between two groups stratified by nomogram score. Methods In this retrospective cohort study, we evaluated 172 p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dd95444a-7812-555d-a283-b680156ba4a2
DOI: 10.21203/rs.3.rs-1620691/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancerDOI 10.21203/rs.3.rs-1620691/v2Read

A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerSemantic proximity Read

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read

Adjuvant Chemotherapy Guidance for pT1-3N0-1 Breast Cancer Patients with HR+, HER2- subtype: a study based on SEER databaseSemantic proximity Read

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity Read

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patientsSemantic proximity Read

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsSemantic proximity Read

Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity Read

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer RecurrenceSemantic proximity Read

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity Read